Mechanism of GPR84 allosteric modulation at a helix 8-proximate site

This study elucidates the structural mechanism of Gi-biased allosteric modulation in the GPR84 receptor by identifying a novel helix 8-proximate binding site for the positive allosteric modulator PSB-16671, which stabilizes a specific receptor conformation to enhance macrophage phagocytosis while avoiding desensitization.

The Gist

The Big Picture: Finding a Secret "Back Door"

Imagine the human body is a massive city, and its cells are buildings. On the walls of these buildings are GPR84 receptors. Think of these receptors as smart security doors that control who gets in and out, and what happens inside the building (like turning on the immune system to fight cancer or inflammation).

For a long time, scientists knew how to open these doors using a "front door key" (an orthosteric agonist). But there was a problem: these keys were a bit clumsy. They opened the door, but they also triggered a "panic alarm" (desensitization) that eventually jammed the lock, making the door useless after a while. Plus, they sometimes opened the wrong side doors, causing unwanted side effects.

This paper is about discovering a secret back door (an allosteric site) on the GPR84 receptor and a special "back door key" (a drug called PSB-16671) that works in a much smarter way.

---

1. The Two Keys: The Front Door vs. The Back Door

• The Front Door Key (OX04539): This is a standard, powerful key. When you use it, the door swings wide open, and the immune system (the "security guard") rushes in to do its job. However, if you use it too much, the guard gets tired and stops responding (desensitization).
• The Back Door Key (PSB-16671): This is a special, high-tech key. It doesn't just open the door; it modifies the lock mechanism itself.
  • The Magic Trick: When you use the Back Door Key alongside the Front Door Key, it makes the Front Door Key work much better and longer.
  • The Bias: Here is the coolest part. The Back Door Key forces the security guard to do only one specific job: eat cancer cells (phagocytosis). It prevents the guard from doing other jobs that would cause the "panic alarm" to go off. This is called biased signaling.

2. The Discovery: Where is the Back Door?

Scientists used a super-powerful microscope (Cryo-EM) to take a 3D X-ray of the receptor. They found something surprising:

• The Location: The Back Door Key (PSB-16671) doesn't go into the main lock. Instead, it wedges itself into a tiny, hidden pocket near the bottom of the door frame (near "Helix 8"), where the door connects to the floor inside the building.
• The Shape: The key is shaped like a dumbbell (two rings connected by a stick). It fits perfectly into this narrow gap, acting like a wedge that holds the door frame in a specific, open position.

3. How It Works: The "Domino Effect"

Imagine the receptor is a complex machine made of gears and levers.

1. The Wedge: When PSB-16671 wedges itself into that bottom pocket, it pushes a specific lever (a part of the door called Helix 8 and TM7) into a new position.
2. The Chain Reaction: This movement triggers a chain reaction of tiny magnets (hydrogen bonds) connecting different parts of the door. It's like a row of dominoes falling.
3. The Result: The dominoes fall in a way that pushes the bottom of the door (TM6) outward.
   • The "Goldilocks" Zone: This outward push is just right for the "Security Guard" (the Gi protein) to grab on and start eating cancer cells.
   • The "Too Big" Problem: However, this push is too far for the "Panic Alarm" (beta-arrestin) to grab on. The alarm mechanism literally can't reach the handle because the door is pushed out too far.

Analogy: Think of a revolving door.

• The Front Door Key spins the door fast. It lets people in, but if it spins too fast, the mechanism breaks, and the door jams.
• The Back Door Key is like a person standing inside the door, holding the frame steady. They don't spin the door themselves, but they make sure that when the Front Door Key turns it, it spins smoothly and only in the direction that lets the good guys in, while physically blocking the bad guys (the alarm) from getting a grip.

4. Why This Matters for Medicine

This discovery is a game-changer for two main reasons:

1. Cancer Immunotherapy: Since this drug keeps the immune system "eating" cancer cells without getting tired (desensitized), it could be a powerful new way to treat cancer. It turns the body's own immune system into a relentless cancer-eating machine.
2. Precision Medicine: Most drugs are like sledgehammers; they hit everything. This drug is like a scalpel. Because it uses a unique "back door" that isn't found on many other receptors, it can be tuned to target only GPR84 without messing up other systems in the body.

5. The "Glitch" That Was Actually a Feature

The scientists found something weird: when they broke a specific part of the "domino chain" (a mutation in the receptor), the Back Door Key actually worked better at cooperating with the Front Door Key.

The Analogy: Imagine a stiff, rusty hinge on a door. If you oil it (break the rigid connection), the door swings more freely. The researchers realized that the receptor needs to be flexible, not rigid, for the Back Door Key to do its job perfectly. By making the internal connections slightly more flexible, the drug could stabilize the "open" position even more effectively.

Summary

This paper is about finding a secret, specialized switch on an immune system receptor. By turning this switch, scientists can create a drug that supercharges the immune system's ability to hunt down cancer cells, while avoiding the side effects and "tiredness" that come with traditional drugs. It's like upgrading a standard door lock to a smart, biometric system that only lets the good guys in and keeps the bad guys out forever.

Technical Summary

1. Problem Statement

GPR84 is an immune-metabolic G protein-coupled receptor (GPCR) involved in innate immunity and macrophage phagocytosis. While orthosteric agonists (like 6-OAU) can activate GPR84 to promote cancer cell phagocytosis, they often induce receptor desensitization at high concentrations, limiting therapeutic efficacy. Allosteric modulators offer a pathway to achieve biased signaling (selectively activating G-proteins over arrestins) and sustained responses, but the structural mechanisms enabling biased allosteric modulation in Class A GPCRs remain poorly understood. Specifically, the binding site and mechanism of action for the GPR84 positive allosteric modulator (PAM) PSB-16671 were previously unknown.

2. Methodology

The study employed an integrated multidisciplinary approach:

• Cryo-Electron Microscopy (Cryo-EM): Determined high-resolution structures of the human GPR84–Gi heterotrimeric complex in two states:
  1. Bound to the orthosteric agonist OX04539 alone.
  2. Bound to both OX04539 and the PAM PSB-16671.
• Molecular Dynamics (MD) Simulations: Used to validate binding modes, analyze conformational stability, and map the allosteric communication network between the orthosteric and allosteric sites.
• Pharmacological Assays:
  • [35S]GTPγS binding: To measure Gi protein activation potency and efficacy.
  • Radioligand competition binding: To determine ligand affinity ($K_d$) and cooperativity factors ($\alpha$).
  • BRET assays: To assess $\beta$-arrestin recruitment.
  • Phagocytosis assays: Using bone marrow-derived macrophages (BMDMs) to evaluate functional outcomes in a physiological context.
• Site-Directed Mutagenesis & SAR: Generated receptor mutants (e.g., Thr411.53Val, Ala372.55Val) and synthesized analogs of PSB-16671 to validate the structural predictions and define structure-activity relationships (SAR).

3. Key Contributions & Results

A. Discovery of a Novel Allosteric Site

• Location: Cryo-EM revealed that PSB-16671 binds to a previously uncharacterized allosteric pocket located at the interface of Transmembrane Helix 1 (TM1), TM7, and Helix 8.
• Distinctiveness: This site is distinct from known intracellular allosteric sites (e.g., ICL2 or G-protein coupling cavity) and differs from negative allosteric modulators (NAMs) in chemokine receptors that sterically block G-protein coupling.
• Binding Mode: PSB-16671, a symmetric bis-indole molecule, adopts an extended conformation. Key interactions include:
  • A hydrogen bond between an indole NH and Thr411.53.
  • Hydrophobic and $\pi$-$\pi$ stacking interactions with residues like Leu401.52, Ala372.55, Tyr381.8.54, and Val368.7.51.
  • MD simulations confirmed a persistent H-bond with Thr411.53 and interactions with the backbone of Thr331.45.

B. Mechanism of Biased Signaling (Gi-Bias)

• Conformational Changes: PSB-16671 stabilizes a receptor conformation characterized by a pronounced outward displacement of the cytoplasmic end of TM6.
• Bias Mechanism: While this large TM6 displacement is optimal for Gi coupling, it is incompatible with productive $\beta$-arrestin recruitment (which typically requires a more modest TM6 movement).
• Functional Outcome: PSB-16671 acts as a Gi-biased ago-PAM. It enhances the potency of orthosteric agonists (OX04539) for Gi activation but does not directly recruit arrestin. Consequently, it sustains macrophage phagocytosis of cancer cells without the desensitization observed with balanced agonists like 6-OAU.

C. Allosteric Communication Network

• Polar Network: The study identified a conserved polar interaction network linking the orthosteric and allosteric sites: Asp662.50 – Asn1043.36 – Asn3627.45 – Tyr3326.48 – Asn3667.49 (NPxxY motif).
• Paradoxical Flexibility: Surprisingly, mutagenesis of key residues in this network (e.g., Asn1043.36Ala and Asn3627.45Ser) enhanced the cooperativity between the orthosteric and allosteric ligands.
• Interpretation: Disrupting specific rigid polar contacts increases the conformational flexibility of the network, allowing PSB-16671 to more effectively stabilize the active state required for agonist binding and Gi coupling.

D. Selectivity and SAR Validation

• Critical Residues: Mutagenesis confirmed that Thr411.53 is essential for PSB-16671 binding (Thr411.53Val mutation abolishes PAM activity but preserves orthosteric agonist function).
• Selectivity: Sequence analysis suggests this site is not universally promiscuous. Variations in residues like Thr411.53 (often apolar in other GPCRs) and Ala372.55 (often bulky Phe/Leu in others) likely prevent PSB-16671 from binding to other Class A GPCRs, although off-target activity at CB1/CB2 was noted via orthosteric mechanisms.

4. Significance

• Structural Expansion: This work defines a third distinct class of allosteric sites in Class A GPCRs (helix 8-proximate), expanding the structural landscape for drug discovery beyond the traditional transmembrane and intracellular loops.
• Mechanistic Insight: It provides a structural basis for biased allosteric modulation, demonstrating how specific conformational changes (extreme TM6 displacement) can selectively favor G-protein signaling over arrestin recruitment.
• Therapeutic Potential: The findings suggest that targeting helix 8-proximate sites could yield therapeutics for immune-metabolic disorders (e.g., fibrosis, inflammation) and cancer immunotherapy that avoid receptor desensitization.
• General Principle: The discovery that conformational flexibility within a polar network enhances allosteric cooperativity offers a new design principle for developing next-generation biased modulators.

In summary, the paper elucidates the structural and dynamic mechanisms by which PSB-16671 modulates GPR84, revealing a novel allosteric site that enables sustained, biased Gi signaling with potential applications in cancer immunotherapy and anti-inflammatory treatments.